NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

HyGro,

Thanks for reposting that again, but you are misinformed. I believe that you need to consider better sources.

While glancing over several of your recent reposts today, this came to mind:

The U.S. NIH has supported the DCVax-L platform for years, and the NIH renewed its support in 2022 to continue to fund the development of this technology and to fund research into combination therapies.

NIH-funded DCVax-L research is ongoing at UCLA today.

NIH grants are peer-reviewed and the research that NIH funds is highly scrutinized in advance of the award and also intermittently for the term of the various research projects.



https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers

Regarding the ECA/crossover design and the SAP, please review the video recording of Dr. Ashkan at ASCO 2022 and the JAMA Oncology podcast recording of Dr. Liau. Both recordings are included at the links below.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171254048;

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171254756;

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171927087;

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172163592;